2024-04-24 12:09:50
1st place in growth rate among domestic gastroesophageal reflux disease treatments
Prescriptions in the first quarter amounted to 17 billion won… Cumulative sales exceeded KRW 83.3 billion since release
“Increased preference for first- and second-generation treatments by improving shortcomings”
Domestic P-CAB market doubled before and after the launch of Pexuclu
This year, good news such as collaboration with Chong Kun Dang and expansion of coverage for gastritis indications
Daewoong Pharmaceutical’s Fexuclu was found to have recorded the highest growth rate in the domestic gastroesophageal reflux disease treatment market.
Daewoong Pharmaceutical announced on the 24th that the prescription amount for Korea’s 34th new drug ‘Fexuclu (ingredient name: Fexuprazan)’ in the first quarter of this year was KRW 17 billion, up 57% from the same period last year.
According to market research company UBIST, among the top 10 gastroesophageal reflux disease treatment products, the prescription performance of seven PPI (proton pump inhibitor) products, which are second-generation treatments, has decreased, but P-CAB (potassium competitive), a third-generation treatment, has decreased. All products in the gastric acid secretion inhibitor (gastric acid secretion inhibitor) series showed growth. Among them, Fexuclu was found to have led the growth of the P-CAB market with a 57% increase in prescriptions.
Fexuclu is a domestically produced new drug released by Daewoong Pharmaceutical in July 2022. As of last month, the cumulative prescription amount recorded 83.3 billion won, making it a blockbuster in a short period of time. In the second year since its release, it has risen to second place in the gastroesophageal reflux disease treatment market and is evaluated as driving the growth of the P-CAB series.
In fact, if you look at the change in the total prescription amount of domestic P-CAB products before and after the launch of Fexuclu, the presence of Fexuclu becomes more noticeable. According to UBIST, the prescription amount for P-CAB products in the first quarter of 2022, before the launch of Pexuclu, was only KRW 31.1 billion, but the total prescription amount in the first quarter of this year more than doubled to KRW 63.8 billion.
The industry analyzed that the 3rd generation P-CAB series treatment is showing rapid growth by dramatically improving the shortcomings of the 1st and 2nd generation gastrointestinal drugs.
The first generation treatment, H2RA (histamine-2 receptor antagonist), was developed in the 1970s. It is a mechanism that partially inhibits gastric acid secretion by involving only one of the three pathways involved in gastric acid secretion, and has been evaluated as having many inherent limitations. The second-generation treatment, the PPI (proton pump inhibitor) series, appeared in 1980. Gastric acid is required in the process of activating the drug, but paradoxically, it has the disadvantage of being weak to stomach acid, reducing the drug’s efficacy and taking a long time to develop. Additionally, it is a drug that must be taken before a meal for maximum effectiveness.
P-CAB series products, a third-generation treatment, have rapid efficacy and effectively suppress gastric acid secretion, so prescription preference is increasing recently. In particular, Fexuclu has a half-life of 9 hours, the longest among gastroesophageal reflux disease treatments including the P-CAB series. This means that the medicinal effect lasts for a long time. The efficacy of the drug lasts for a long time, and it is evaluated to be positive in alleviating nighttime heartburn symptoms. Daewoong Pharmaceutical explained that it has also secured data on improving chronic coughing. Unlike PPI, P-CAB has a mechanism whereby the drug binds to the proton pump and quickly and stably suppresses gastric acid secretion without the process of drug activation by stomach acid. Indications for Fexuclu include erosive gastroesophageal reflux disease, acute gastritis, and improvement of gastric mucosal lesions in chronic gastritis. For gastritis indications, Fexuclu is the only P-CAB class agent in Korea.
Recently, Daewoong Pharmaceutical decided to join hands with Chong Kun Dang to jointly sell Fexuclu to strengthen its market presence. The plan is to maximize synergy by conducting joint sales and marketing in earnest. In the second half of this year, coverage for gastritis indications will be expanded, and prescription performance is expected to grow once again.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, “As P-CAB is emerging as a trend in the gastrointestinal drug market, Pexuclu is serving as a driving force driving growth.” He added, “This year, through collaboration with Chong Kun Dang and expansion of coverage for gastritis indications, we ranked first in the domestic gastrointestinal drug market. “We will accelerate our efforts to penetrate the market with the goal of achieving sales of 300 billion won by 2030,” he said.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news now
2024-04-24 12:09:50